#United States #Los Angeles #FDA Approval #Thyroid Ablation #STARMED America

STARMED Achieves a Historic Milestone with FDA Clearance

In an impressive stride for medical technology, STARMED America has recently secured the FDA 510(k) clearance for the first-ever radiofrequency ablation (RFA) device specifically designed for treating thyroid nodules in the United States. This landmark achievement positions STARMED as the pioneering company to hold an FDA indication for this procedure, underscoring its role in offering innovative healthcare solutions.

Thyroid nodules are a significant concern, affecting approximately 65% of the U.S. population. Traditionally, patients dealing with benign nodules faced two primary options: continuous monitoring or invasive surgical intervention. The newfound RFA technology from STARMED opens a new avenue, providing a minimally invasive outpatient alternative that not only preserves the thyroid but also reduces the necessity for surgery.

The FDA clearance encompasses STARMED’s VIVA combo RF generator and several RF electrodes, which are now authorized for ultrasound-guided percutaneous ablation of benign thyroid nodules in adults. Criteria for treatment include symptomatic nodules, those causing cosmetic concerns, and autonomously functioning nodules, provided their volume is below 10 mL. The decision to grant this clearance was supported by rigorous empirical evidence, including a systematic review of 42 peer-reviewed publications, demonstrating that the technology consistently achieves a volume reduction ratio (VRR) of at least 50% within six months. This benchmark is essential for alleviating symptoms effectively.

For healthcare professionals, this FDA clearance is expected to facilitate the process of integrating this technology into clinical practice, ensuring alignment among device labeling, clinical evidence, and relevant coding pathways. This milestone not only represents a leap forward in patient care but also reflects the years of dedication put forth by STARMED. The company, which started its journey in June 2002 when Dr. Jung Hwan Baek conducted the world’s first thyroid RFA procedure in South Korea using STARMED equipment, has established itself as a leader in medical innovation.

Henry Shin, CEO of STARMED Co., Ltd, stated, “From the first thyroid RFA procedure ever performed to the first FDA indication in U.S. history, STARMED has been the equipment behind the science.” This sentiment captures the unwavering commitment of STARMED to excellence and innovation in the field of medical technology.

The clearance symbolizes not just a regulatory win but also a testament to the trust that physicians and researchers worldwide have in STARMED’s technology after more than two decades of impactful contributions to the medical community. As the landscape of thyroid treatment continues to evolve, STARMED America is poised to lead it with their cutting-edge solutions.

For further information about STARMED's groundbreaking technology or the specifics of the FDA indication, interested parties can visit STARMED America’s website.

This groundbreaking advancement showcases the potential of radiofrequency ablation to transform medical practices and enhance patient outcomes, and it solidifies STARMED’s place as an innovator in this critical field. As the company moves forward, stakeholders in the healthcare sector will undoubtedly be paying close attention to how this technology will change the approach to thyroid care and set new standards for treatment efficacy and patient safety.